Shenzhen Glory Medical Co Ltd (002551) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Shenzhen Glory Medical Co Ltd stock ¥0.81, price ¥2.96, that is 72.6% below the price, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range ¥2.20 – ¥6.41 · fair‑value band ¥0.7300 – ¥0.9100 · the ¥2.96 price screens above the ¥0.8100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Shenzhen Glory Medical Co in your weekly email
Every Wednesday you see whether Shenzhen Glory Medical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Shenzhen Glory Medical Co.,Ltd. offers hospital construction and medical system integrated solutions in China and internationally. It operates through Medical Products, Medical Services, and Health Industry segments.
Show moreShow less
The company is involved in the planning, design, management, and implementation of hospital construction projects; installation of medical professional engineering projects; and medical software development activities.
It also sells medical information solutions comprising digital operating rooms, surgical teaching systems, remote surgical consultation, mobile digital video station, central management platforms, and digital pre-hospital emergency platforms.
In addition, the company provides medical protective equipment, including non-woven medical surgical gown and bag, medical disposable protective clothing, and disposable isolation gowns, as well as medical disposable masks; and medical consumables.
Further, the company provides professional hospital digital solutions; medical services; hospital overall design and consulting services; and hospital and logistics management services. The company invests in and operates health industry parks, business incubation, and cultivation.
Shenzhen Glory Medical Co.,Ltd. was founded in 1998 and is based in Shenzhen, China.
Stock analysis
Shenzhen Glory Medical Co Ltd (002551) currently trades at ¥2.96, while our model-based Fair Value estimate is ¥0.8100, 73% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ¥0.8050 per share, and 0 of the 10 models we run sit above the ¥2.96 price.
Bear case: the DCF Models group reads lowest at ¥0.7500, and 10 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥0.7300 (bear) to ¥0.9100 (bull), the price of ¥2.96 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2017: revenue and profit before it include the divested business. Growth is measured afresh from 2017.
Shenzhen Glory Medical Co Ltd reported revenue of 1.1B CNY in FY2025 versus 1.8B CNY in FY2021, a compound −11.9%/yr. Reported net income was −140M CNY in FY2025.
Key figures
Market cap 2.5B CNY (≈ $375M) Small · P/S ratio 2.22 · EPS (TTM) ¥−0.1700 · Dividend yield 0.9% · Net margin −11.8% · Return on equity −5.6% · Return on assets (EBIT) −2.5% (5-year average) · Operating margin −3.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (medium confidence).
What moves the price
The share trades about 29% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at −73%, 002551 screens richer than that median.
Fair Value models
Bear¥0.7300Fair Value ¥0.8100Bull¥0.9100
Price ¥2.96 · Downside -72.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2017: revenue and profit before it include the divested business. Growth is measured afresh from 2017.
Revenue growth 1 year
−25.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.8%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.3% (2020) → −7.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+44.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +42.1% a year for the price.
Compare Shenzhen Glory Medical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks
Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside−72.6% · Bottom 25%
Profitability
Return on assets−4.2% · Bottom 25%
Net margin (12 months)−11.8% · Bottom 25%
Operating margin (12 months)−3.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)19.7% · Top 25%
Dividend yield (12 months)0.9% · Bottom 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Shenzhen Glory Medical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/002551
Frequently asked questions
Is Shenzhen Glory Medical Co Ltd (002551) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of ¥0.8100 versus a price of ¥2.96, about 73% lower (overvalued).
What is the fair value of 002551?
Our model-based fair value for Shenzhen Glory Medical Co Ltd is ¥0.8100 (as of Nov 8, 2026), built from audited fundamentals. The current price: ¥2.96.
What is the quality score of 002551?
Shenzhen Glory Medical Co Ltd has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shenzhen Glory Medical Co Ltd (002551)?
Our model-based price target is the fair value of ¥0.8100 (as of Nov 8, 2026) from 10 valuation models. Cautious scenario ¥0.7300, optimistic scenario ¥0.9100. It is a calculation from audited fundamentals, not an analyst target.
What is the Shenzhen Glory Medical Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.8100, about 73% lower versus a price of ¥2.96 (overvalued). Cautious scenario ¥0.7300, optimistic scenario ¥0.9100. The calculation is refreshed regularly with new filings.
What is the revenue of Shenzhen Glory Medical Co Ltd (002551)?
Shenzhen Glory Medical Co Ltd reported trailing-twelve-month revenue of about 1.2B CNY (latest available figure, as of Nov 8, 2026).
Does Shenzhen Glory Medical Co Ltd pay a dividend?
Shenzhen Glory Medical Co Ltd currently shows a dividend yield of 0.87% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Shenzhen Glory Medical Co Ltd (002551)?
Shenzhen Glory Medical Co Ltd has a dividend yield of 0.9%.
What growth is priced into Shenzhen Glory Medical Co Ltd (002551)?
For today's price to be fair in a discounted-cash-flow model, Shenzhen Glory Medical Co Ltd would have to grow free cash flow by +44.5 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -13.8 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of 002551 use?
Our models discount Shenzhen Glory Medical Co Ltd at 10.4 %: a base by market capitalisation (small), damped by beta 0.43, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shenzhen Glory Medical Co Ltd that is +44.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Shenzhen Glory Medical Co Ltd (002551) delivered so far?
Over the past 5 years revenue at Shenzhen Glory Medical Co Ltd grew -13.8 % a year. The price currently implies free-cash-flow growth of +44.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Shenzhen Glory Medical Co Ltd (002551) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into Shenzhen Glory Medical Co Ltd (+44.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Shenzhen Glory Medical Co Ltd (002551)?
The free-cash-flow yield on the price is 0.60 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Shenzhen Glory Medical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Shenzhen Glory Medical Co Ltd (002551)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shenzhen Glory Medical Co Ltd it is ¥0.8100 per share (as of Nov 8, 2026), against a price of ¥2.96. It is the blended result of 10 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Shenzhen Glory Medical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 002551 trades above its calculated fair value: price ¥2.96, fair value ¥0.8100, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002551?
No. The price is what the market pays today (¥2.96); the fair value is what the company's own numbers justify (¥0.8100). For Shenzhen Glory Medical Co Ltd the two are ¥2.15 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shenzhen Glory Medical Co Ltd worth?
The market values Shenzhen Glory Medical Co Ltd at about 2.5B CNY (market capitalisation, as of Nov 8, 2026). Per share that is ¥2.96; our models calculate a fair value of ¥0.8100 per share.
What do the bullish and bearish scenarios say about 002551?
Our models span a range for Shenzhen Glory Medical Co Ltd: cautious scenario ¥0.7300, base ¥0.8100, optimistic ¥0.9100 per share (as of Nov 8, 2026, price ¥2.96). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shenzhen Glory Medical Co Ltd (002551)?
Balance-sheet figures for Shenzhen Glory Medical Co Ltd (as of Nov 8, 2026): return on equity −5.6%, debt of 0.00 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is 002551 from its 52-week high?
Shenzhen Glory Medical Co Ltd trades at ¥2.96, about 29% below its 52-week high of ¥4.16 and 11% above the low of ¥2.67 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.8100 is for.
Which stocks are comparable to Shenzhen Glory Medical Co Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shenzhen Glory Medical Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price ¥2.96, calculated fair value ¥0.8100 (−73%), Quality Score 45/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002551 calculated?
We run Shenzhen Glory Medical Co Ltd through 10 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of ¥0.8100 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shenzhen Glory Medical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shenzhen Glory Medical Co Ltd (002551)?
The closing price on Nov 6, 2026 was ¥2.96. Our model-based fair value is ¥0.8100, about 73% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shenzhen Glory Medical Co Ltd right now?
The price sits above even our optimistic bull case (¥0.9100). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Shenzhen Glory Medical Co Ltd
How large is the market capitalisation of Shenzhen Glory Medical Co Ltd (002551)?
The market capitalisation of Shenzhen Glory Medical Co Ltd is 2.5B CNY (≈ $375M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shenzhen Glory Medical Co Ltd (002551)?
The price-to-sales ratio of Shenzhen Glory Medical Co Ltd is 2.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shenzhen Glory Medical Co Ltd (002551)?
Earnings per share at Shenzhen Glory Medical Co Ltd are ¥−0.1700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shenzhen Glory Medical Co Ltd (002551)?
The dividend yield of Shenzhen Glory Medical Co Ltd is 0.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shenzhen Glory Medical Co Ltd (002551)?
The net margin of Shenzhen Glory Medical Co Ltd is −11.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shenzhen Glory Medical Co Ltd (002551)?
The return on equity (ROE) of Shenzhen Glory Medical Co Ltd is −5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shenzhen Glory Medical Co Ltd (002551)?
On an EBIT basis the return on assets of Shenzhen Glory Medical Co Ltd is −2.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shenzhen Glory Medical Co Ltd (002551)?
The operating margin of Shenzhen Glory Medical Co Ltd is −3.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shenzhen Glory Medical Co Ltd (002551)?
Revenue at Shenzhen Glory Medical Co Ltd is growing +19.7% versus a year earlier (3y avg −5.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Shenzhen Glory Medical Co Ltd (002551) hold?
Shenzhen Glory Medical Co Ltd holds more cash than debt, 459M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Shenzhen Glory Medical Co Ltd in the live analysis
One click puts Shenzhen Glory Medical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026